# EDGAR Filing Document

**Accession Number:** 0001527728
**File Stem:** 0001731122-26-000718
**Filing Date:** 2026-5
**Character Count:** 5886
**Document Hash:** 3b56b56962d60d4342f3ca401b40580b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001731122-26-000718.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001731122-26-000718

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260508

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lunai Bioworks Inc.
- **CENTRAL INDEX KEY:** 0001527728
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452259340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38758
- **FILM NUMBER:** 26974172

**BUSINESS ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067
- **BUSINESS PHONE:** 45 39179840

**MAIL ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RENOVARO INC.
- **DATE OF NAME CHANGE:** 20240213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RENOVARO BIOSCIENCES INC.
- **DATE OF NAME CHANGE:** 20230807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Enochian Biosciences Inc.
- **DATE OF NAME CHANGE:** 20230804

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 8, 2026**

**LUNAI BIOWORKS, INC.**

*(Exact name of registrant as specified in its charter)*

---

| | | |
|:---|:---|:---|
| **Delaware**<br> (State or other jurisdiction<br> of incorporation) | **001-38758**<br> (Commission<br> File Number) | **45-2259340**<br> (I.R.S. Employer<br> Identification No.) |

---

**3400 Cottage Way, Suite G2, #3256**

**Sacramento, California 95825**

*(Address of principal executive offices)*

**(424) 222-9301**

*(Registrant's telephone number, including area code)*

**Not Applicable**

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share LNAI | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On May 8, 2026, the Company held a special meeting of stockholders. The final voting results for the proposals submitted to a vote of stockholders are set forth below.

**Proposal 1:** To approve an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split of the outstanding shares of the Company's common stock at a ratio in the range of 1-for-3 to 1-for-30, with the exact ratio to be determined by the Company's Board of Directors in its sole discretion.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** | **Result** |
| 13,571,288 | 1,153,415 | 61,177 | 0 | Approved |

---

**Proposal 2:** To approve the adjournment of the Special Meeting, if necessary or appropriate, including to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve Proposal 1.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** | **Result** |
| 13,626,029 | 1,091,528 | 68,323 | 0 | Approved |

---

**Forward-Looking Statements**

This Current Report on Form 8-K contains forward-looking statements regarding the Company's ability to regain or maintain compliance with applicable Nasdaq continued listing requirements, the implementation and effects of the reverse stock split, and the continued listing of the Company's common stock on The Nasdaq Capital Market. These statements are subject to risks and uncertainties, including the risk that the reverse stock split does not result in compliance with the Bid Price Rule, the consequences of the Mandatory Panel Monitor described above, and the other risks described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **LUNAI BIOWORKS, INC.** | **LUNAI BIOWORKS, INC.** |
| Date: May 13, 2026 | Date: May 13, 2026 |
| By: | */s/ David Weinstein* |
| Name: | David Weinstein |
| Title: | Chief Executive Officer |

---